Trial · NCT07464366
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
NCT07464366, Phase 2, Recruiting, Ji Dongmei
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study. Trials, record NCT07464366. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07464366
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
- NCT number
- NCT07464366
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Ji Dongmei
- Conditions
- Salivary Gland Carcinomas
- Interventions
- MRG 003, Pucotenlimab
- First posted
- 2026-03-11
- Last updated
- 2026-04-01
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The objective response rate (ORR) was evaluated by investigators using RECIST 1.1 criteria. | From the date of the first dose of Cycle 1 (each cycle is 21 days) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. | The objective response rate (ORR) is defined as the proportion of subjects in whom the tumor has achieved either complete remission (CR) or partial remission (PR) following treatment. |
| Secondary | Disease Control Rate (DCR) assessed by the investigator according to RECIST v1.1 criteria | From the date of the first dose of Cycle 1 (each cycle is 21 days) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. | The disease control rate (DCR) is defined as the proportion of subjects in the full analysis set (FAS) whose best overall response is either complete response (CR), partial response (PR), or stable disease (SD) based on investigator assessment using RECIST v1.1. Subjects with SD must have maintained SD for at least 6 weeks from the first dose to be counted as disease control. |
| Secondary | Duration of Response | From the date of the first objective response (according to Recist 1.1) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. | The time from the first documented evidence of objective response (CR or PR) to the first documented disease progression or death from any cause, whichever occurred first. |
| Secondary | Progression-Free Survival | From the date of the first dose of Cycle 1 (each cycle is 21 days) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. | The time from the first dose to the first documented disease progression as determined by investigator assessment according to RECIST v1.1, or death from any cause, whichever occurred first. |
| Secondary | Overall survival | From the date of the first dose of Cycle 1 (each cycle is 21 days) until the date of death from any cause, assessed up to 60 months. | The time from first dose to death from any cause. |
| Secondary | Safety Assessments | From the date of the first dose of Cycle 1 (each cycle is 21 days) until the date 30 days after last dose or the date of death, whichever occurs first, assessed up to 60 months. | Adverse events (AEs) and serious adverse events (SAEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0). The incidence and severity of AEs and SAEs, as well as laboratory abnormalities, will be evaluated and summarized. |
| Secondary | Dose Modification and Discontinuation Rates | From the date of the first dose of Cycle 1 (each cycle is 21 days) until the date 30 days after last dose or the date of death, whichever occurs first, assessed up to 60 months. | The following safety endpoints were evaluated: Rate of dose interruptions due to AEs Rate of dose reductions due to AEs Rate of treatment discontinuations due to AEs Incidence of deaths (including on-study deaths and deaths within 30 days of last dose) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07464366
GET https://conductscience.org/api/trials/v1/NCT07464366/registered